MedTrace Logo

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

NCT05442788 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-07-07

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, dose-escalation Phase Ib study to evaluate the safety, tolerability, and pharmacokinetics of HB0017 following multiple dose in patients with moderate to severe plaque psoriasis.

Conditions

Interventions

BIOLOGICAL

HB0017 150mg or matching placebo

Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.

BIOLOGICAL

HB0017 300mg or matching placebo

Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.

BIOLOGICAL

HB0017 450mg or matching placebo

Each subject receive injection at week0(Day1), week 3(Day22), week 6(Day43) and week 9(Day64), respectively.

Sponsors & Collaborators

  • Huabo Biopharm Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Congjun Jiang, Master · The First Affiliated Hospital of Bengbu Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-02
Primary Completion
2022-05-31
Completion
2022-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05442788 on ClinicalTrials.gov